Texas-based plasmid DNA Manufacturer VGXI, Inc. to Enable Accelerated Production of a Vaccine against the 2019 Novel Coronavirus in a CEPI Funded Collaboration The Woodlands, TX – VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV)… Read More »
Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines. The Woodlands, TX – VGXI announces successful implementation of new RNA production services through completion of all Phase II initiatives as part of a… Read More »
Plasmid DNA Manufacturer VGXI, Inc. Selects BE&K Building Group as its Design-Build Partner for the Initial Phase of its New and Expanded Manufacturing Facility December 3, 2019, The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services… Read More »
The ISV Annual Congress is the world’s largest scientific conference in the field of vaccines and covers a broad range of topics related to vaccines and immunotherapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing… Read More »
The 26th International Symposium on Hepatitis C Virus and Related Viruses focuses on the advancement of HCV and related virus research, vaccines, and therapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing services and experience!… Read More »
The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Be sure to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn how VGXI’s… Read More »
Industry recognized plasmid DNA manufacturer VGXI, Inc. to support production of personalized cancer therapies as part of a long-term supply agreement with Geneos Therapeutics. June 22, 2019, The Woodlands, TX and Plymouth Meeting, PA – Plasmid CMO VGXI, Inc. and Geneos Therapeutics, Inc., a spin-out of Inovio Pharmaceuticals (NASDAQ: INO) focused on developing… Read More »
A new and completely redesigned website offers visitors a comprehensive overview of VGXI’s range of plasmid DNA manufacturing services and capabilities. May 20, 2019, The Woodlands, TX – Texas based CMO VGXI, Inc., which specializes in production of DNA plasmid biopharmaceuticals, announced it has gone live with a refreshed website and online… Read More »
With over 16,000 attendees, BIO is one of the largest biotech partnering, education, and networking events in the world. Be sure to stop by VGXI’s Booth #3349 or schedule a meeting with one of our representatives during the conference to learn how VGXI’s plasmid manufacturing services can support your gene or cell therapy program! Contact Us directly… Read More »
Plasmid CMO VGXI will be speaking at the 22nd Annual ASGCT Meeting in Washington DC. April 04, 2019, The Woodlands, TX – VGXI, Inc., an industry leading plasmid DNA contract manufacturing organization today announced that Mr. Stephen Rodriguez, Sr. Manager, Process Development, will be presenting during the Tools and Technologies Forum of… Read More »
The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. Visit VGXI’s Booth #411 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene or… Read More »
Texas based CMO VGXI Announces Completion of Initial Tech Transfer Milestones as part of its Partnership Agreement for Production of RNA Therapeutics with HMRI. March 15, 2019, The Woodlands, TX – Under a license agreement with the Houston Methodist Research Institute (HMRI) for development of clinical grade RNA manufacturing services, VGXI announced… Read More »
Sign Up
For more information